148 related articles for article (PubMed ID: 6926923)
1. View from the Nation's Capitol.
Romansky MA
J Clin Psychopharmacol; 1982 Feb; 2(1):74-5. PubMed ID: 6926923
[No Abstract] [Full Text] [Related]
2. View from the Nation's Capitol.
Freishtat HW
J Clin Psychopharmacol; 1982 Apr; 2(2):146-8. PubMed ID: 6926924
[No Abstract] [Full Text] [Related]
3. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
[No Abstract] [Full Text] [Related]
4. View from the nation's capital.
Romansky MA
J Clin Psychopharmacol; 1985 Feb; 5(1):51-2. PubMed ID: 2982923
[No Abstract] [Full Text] [Related]
5. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA).
Romansky MA
J Clin Psychopharmacol; 1983 Jun; 3(3):193-4. PubMed ID: 6680405
[No Abstract] [Full Text] [Related]
6. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations.
Romansky MA
J Clin Psychopharmacol; 1983 Dec; 3(6):380-3. PubMed ID: 6680409
[No Abstract] [Full Text] [Related]
7. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
8. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Feb; 4(1):52-4. PubMed ID: 6096407
[No Abstract] [Full Text] [Related]
9. View from the Nation's Capital. FDA moves forward (and backwards) on a number of simmering issues.
Appler WD
J Clin Psychopharmacol; 1988 Feb; 8(1):57-8. PubMed ID: 3351001
[No Abstract] [Full Text] [Related]
10. View from the Nation's Capital.
Freishtat HW
J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
[No Abstract] [Full Text] [Related]
11. Standards for institutional review boards for clinical investigations: proposed establishment of regulations.
Fed Regist; 1978 Aug; 43(153):5185-208. PubMed ID: 10237259
[No Abstract] [Full Text] [Related]
12. Drug advisory committees. Getting outside advice for close calls.
Farley D
FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
[No Abstract] [Full Text] [Related]
13. Professional drug labeling.
Terry M
J Am Vet Med Assoc; 1993 May; 202(10):1711-2;discussion 1713-7. PubMed ID: 8514591
[No Abstract] [Full Text] [Related]
14. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1986 Feb; 6(1):42-4. PubMed ID: 3950066
[No Abstract] [Full Text] [Related]
15. Position statement of the AFCR on the issue of regulation of institutional review boards by the FDA.
Clin Res; 1979 Apr; 27(2):109-11. PubMed ID: 10241073
[No Abstract] [Full Text] [Related]
16. View from the Nation's Capitol.
Freishtat HW
J Clin Psychopharmacol; 1982 Jun; 2(3):219-20. PubMed ID: 6927305
[No Abstract] [Full Text] [Related]
17. The IRB as deputy sheriff: proposed FDA regulation of the institutional review board.
Huff TA
Clin Res; 1979 Apr; 27(2):103-8. PubMed ID: 10241072
[No Abstract] [Full Text] [Related]
18. The regulatory role of the United States Food and Drug Administration.
Ortiz EM
J Reprod Med; 1972 Apr; 8(4):205-6. PubMed ID: 5029971
[No Abstract] [Full Text] [Related]
19. Developing the nation's biosimilars program.
Kozlowski S; Woodcock J; Midthun K; Sherman RB
N Engl J Med; 2011 Aug; 365(5):385-8. PubMed ID: 21812668
[No Abstract] [Full Text] [Related]
20. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
